Tibolone and Risk of Gynecological Hormone Sensitive Cancer

International Journal of Cancer - United States
doi 10.1002/ijc.31267
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Risk Factors, Risk Assessment, and Prognosis in Patients With Gynecological Cancer and Thromboembolism

Journal of International Medical Research
BiochemistryMedicineCell Biology
2019English

Eyeing Enzalutamide for Hormone-Sensitive Prostate Cancer

Cancer Discovery
Oncology
2019English

Estimating Utilities / Disutilities for High Risk Metastatic Hormone-Sensitive Prostate Cancer (MHSPC) and Treatment-Related Adverse Events

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Risk of Cancer After Growth-Hormone Treatment

The Lancet
Medicine
2002English

Hormone Replacement Therapy and Risk of Epithelial Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
1999English

Correction To: Recognizing Gynecological Cancer in Primary Care: Risk Factors, Red Flags, and Referrals

Advances in Therapy
MedicinePharmacology
2018English

Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-Sensitive and Hormone-Resistant Prostate Cancer Cells

Scientific Reports
Multidisciplinary
2019English

Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2009English

Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy